A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)

- 3
- 4 Stephen R. Walsh ^{1,2,*, ‡}, Cynthia L. Gay ^{3,*}, Shelly T. Karuna ⁴, Ollivier Hyrien ⁴, Timothy
- 5 Skalland ⁴, Kenneth H. Mayer ^{2,5}, Magdalena E. Sobieszczyk ⁶, Lindsey R. Baden ^{1,2},
- 6 Paul A. Goepfert ⁷, Carlos del Rio ⁸, Guiseppe Pantaleo ⁹, Philip Andrew ¹⁰, Carissa
- 7 Karg⁴, Zonglin He⁴, Helen Lu⁴, Carmen A. Paez⁴, Jane A. G. Baumblatt¹¹, Laura L.
- 8 Polakowski ¹¹, Wairimu Chege ¹¹, Sophie Janto ⁴, Xue Han ^{4,⊕}, Yunda Huang ⁴, Julie
- 9 Dumond ¹², Margaret E. Ackerman ¹³, Adrian B. McDermott ¹¹, Britta Flach ¹¹, Estelle
- ¹⁰ Piwowar-Manning ¹⁴, Kelly Seaton ¹⁵, Georgia D. Tomaras ¹⁵, David C. Montefiori ¹⁵,
- 11 Lucio Gama ¹¹, John R. Mascola ^{16, ¶}, for the HVTN 127/HPTN 087 Study Team
- 12
- ¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA
- 14 ² Harvard Medical School, Boston, MA
- ³ Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC
- ⁴ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
- ¹⁷ ⁵ Fenway Institute, Boston, MA
- ⁶ Division of Infectious Diseases, Columbia University, New York, NY
- ¹⁹ ⁷ University of Alabama at Birmingham, Birmingham, AL
- ⁸ Emory University School of Medicine and Ponce de Leon Center of the Grady Health
 System, Atlanta, GA
- ⁹ Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- ¹⁰ FHI 360, Durham, NC
- ¹¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD
- ¹² Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC
- ¹³ Thayer School of Engineering, Dartmouth College, Hanover, NH
- ¹⁴ Johns Hopkins University, Baltimore, MD

- ¹⁵ Department of Surgery and Duke Human Vaccine Institute, Duke University, Durham,
 NC
- ¹⁶ Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
- 31 Bethesda, MD
- 32
- ³³ * These authors contributed equally.
- 34 ¶ Present Address: ModeX Therapeutics, Natick, MA
- 36
- 37 Word count of text: 5249
- 38 Word Count of Abstract: 471
- 39 **Running Title:** VRC07-523LS safety and PK
- 40
- 41 [‡]Corresponding Author:
- 42 Dr. Stephen R. Walsh
- 43 Division of Infectious Diseases
- 44 Brigham & Women's Hospital
- 45 75 Francis Street, PBB-A-4
- 46 Boston, MA 02115
- 47 Telephone: +1-617-525-8418
- 48 Fax: +1-617-732-6829
- 49 E-mail: swalsh@bwh.harvard.edu
- 50
- 51 **Disclaimer**: This article was written by some authors [JAGB, LLP, WC, ABM, BF, LG,
- JCM] in their capacity as employees of the National Institutes of Health (NIH), but the
- views expressed herein do not necessarily represent those of the NIH.
- 54

55 Abstract

56

57 **Background**: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the only bnAb HIV prevention efficacy studies to date, the Antibody 58 59 Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly 60 neutralization-sensitive viruses but was ineffective against less sensitive viruses. 61 62 Greater efficacy is required before passively administered bnAbs become a viable 63 option for HIV prevention; furthermore subcutaneous (SC) or intramuscular (IM) administration may be preferred. VRC07-523LS is a next-generation bnAb targeting the 64 65 CD4-binding site and was engineered for increased neutralization breadth and half-life. Methods: Participants were recruited between 02 February 2018 and 09 October 2018. 66 67 124 healthy participants without HIV were randomized to receive five VRC07-523LS 68 administrations via IV (T1: 2.5 mg/kg, T2: 5 mg/kg, T3: 20 mg/kg), SC (T4: 2.5 mg/kg, T5: 5 mg/kg) or IM (T6: 2.5 mg/kg or P6: placebo) routes at four-month intervals. Safety 69 data were collected for 144 weeks following the first administration. VRC07-523LS 70 serum concentrations were measured by ELISA after the first dose through Day 112 in 71 all participants and by binding antibody multiplex assay (BAMA) thereafter in 60 72 73 participants (10 per treatment group) through Day 784. Compartmental population 74 pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum 75 pharmacokinetics. Neutralization activity was measured in a TZM-bl assay and anti-drug antibodies (ADA) were assayed using a tiered bridging assay testing strategy. 76

77	Results: Injections were well-tolerated, with mild pain or tenderness reported commonly
78	in the SC and IM groups, and mild to moderate erythema or induration reported
79	commonly in the SC groups. Infusions were generally well-tolerated, with infusion
80	reactions reported in 3 of 20 participants in the 20 mg/kg IV group. Peak geometric
81	mean (GM) concentrations (95% confidence intervals) following the first administration
82	were 29.0 μg/mL (25.2, 33.4), 58.5 μg/mL (49.4, 69.3), and 257.2 μg/mL (127.5, 518.9)
83	in T1-T3 with IV dosing; 10.8 μg/mL (8.8, 13.3) and 22.8 μg/mL (20.1, 25.9) in T4-T5
84	with SC dosing; and 16.4 $\mu\text{g/mL}$ (14.7, 18.2) in T6 with IM dosing. Trough GM
85	concentrations immediately prior to the second administration were 3.4 μ g/mL (2.5, 4.6),
86	6.5 μ g/mL (5.6, 7.5), and 27.2 μ g/mL (23.9, 31.0) with IV dosing; 0.97 μ g/mL (0.65, 1.4)
87	and 3.1 $\mu\text{g/mL}$ (2.2, 4.3) with SC dosing, and 2.6 $\mu\text{g/mL}$ (2.05, 3.31) with IM dosing.
88	Peak VRC07-523LS serum concentrations increased linearly with the administered
89	dose. At a given dose, peak and trough concentrations, as well as serum neutralization
90	titres, were highest in the IV groups, reflecting the lower bioavailability following SC and
91	IM administration. A single participant was found to have low titre ADA at a lone
92	timepoint. VRC07-523LS has an estimated mean half-life of 42 days (95% CI: 40.5,
93	43.5), approximately twice as long as VRC01.

Conclusions: VRC07-523LS was safe and well-tolerated across a range of doses and
 routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.

96

Trial Registration: http://www.clinicaltrials.gov/ Identifier: NCT03387150 (posted on 21
 December 2017)

99

100	Potential Conflict of Interest: SRW has conducted clinical trials funded by Janssen
101	Vaccines, Moderna, Pfizer, Vir, Worcester HIV Vaccine, and Sanofi Pasteur, and serves
102	on Independent Data Monitoring Committees for Janssen Vaccines and BioNTech;
103	SRW's spouse is an employee of Regeneron Pharmaceuticals and may hold stock
104	and/or stock options. CLG has received research support from Gilead and ViiV
105	Healthcare and conducted clinical trials funded by Moderna and Novavax. MEA has
106	received research support from Janssen, Be Bio, and Moderna.
107	
108	Funding: US National Institutes of Health (NIH) [www.nih.gov] grants UM1 AI068614
109	(STK, CK, CAP, SJ, GDT), UM1 Al068635 (OH, ZH, HL, YH), UM1 Al068618 (KS,
110	GDT, DCM), UM1 AI069412 (SRW, LRB), UL1 RR025758 (LRB), P30 AI50410 (CLG),
111	UM1 AI069423 (CLG), UM1 AI068619 (PA, JD), UM1 AI068617 (TS), UM1 AI068613
112	(EPM), UM1 TR004406 (CLG). JAGB, LLP, and WC are/were Medical Officers with the
113	National Institute of Allergy and Infectious Diseases (NIAID)/NIH and ABM, BF, LG, and
114	JCM are/were Staff Scientists with NIAID/NIH. The funder had no other role in the study
115	design, data collection and analysis, decision to publish, or preparation of the
116	manuscript.
117	
118	Presented in part at: HIV R4P 2021 Virtual (Abstract OA03.01), Cape Town, South

120

119

5

Africa, January 2021; and IAS 2022 (Abstract PESUA14), Montréal, Canada, July 2022

121 Details of the oversight body: The Partners Human Research Committee of Brigham

- and Women's Hospital gave ethical approval of this work. The Centre Hospitalier
- 123 Universitaire Vaudois Institutional Review Board of the Centre Hospitalier Universitaire
- 124 Vaudois gave ethical approval of this work. The Fred Hutchinson Cancer Research
- 125 Center Institutional Review Board gave ethical approval of this work done at the
- 126 University of North Carolina at Chapel Hill, the Ponce de Leon/Emory University, and
- 127 the University of Alabama at Birmingham. The Fenway Health Institutional Review
- Board of the Fenway Institute gave ethical approval of this work.

130 Introduction

131	Despite the proven effectiveness of behavioural and pharmacological methods of
132	preventing HIV-1 (1-3), worldwide over 1.5 million individuals are estimated to acquire
133	HIV yearly (4). Accordingly, long-acting and well-tolerated biomedical prevention
134	approaches such as passive immunization using broadly neutralizing antibodies
135	(bnAbs) are a promising new approach for HIV-1 prevention (5, 6). In the only efficacy
136	trials of a bnAb against HIV-1 conducted to date, the Antibody Mediated Prevention
137	(AMP) trials, overall efficacy was limited (7). Importantly however, the AMP studies
138	provided proof of concept that passive immunization with a bnAb could confer protection
139	against HIV-1 infection and identified neutralization as a correlate of protection (8).
140	Despite overall low efficacy, viruses that were highly sensitive to neutralization by
141	VRC01 (IC ₈₀ <1 μ g/mL) were successfully blocked in vivo (7, 8). This result suggests
142	that bnAbs with increased breadth and increased potency might provide increased
143	protection.

Toward this aim, another antibody (VRC07) was identified from the same donor as 144 VRC01, cloned, and then engineered to increase its neutralization potency and breadth 145 146 (7). Additional mutations (Met428Leu and Asn434Ser; -LS) were made to the Fc portion of the antibody to increase the antibody's binding affinity for the neonatal Fc receptor 147 (FcRn), resulting in increased recirculation and therefore a longer half-life in vivo (8, 9). 148 The resultant antibody, VRC07-523LS, was 5-to 8-fold more potent than VRC01 and 149 150 considerably broader in vitro, with an $IC_{50} < 1 \mu g/mL$ against 92% of HIV-1 pseudoviruses across circulating HIV-1 clades (7). In a first-in-human, dose-escalation 151 study (VRC 605), VRC07-523LS administered intravenously (IV) to healthy volunteers 152

without HIV was safe, well-tolerated, and found to have a half-life of 38 days, more than
twice the half-life of VRC01 (10).

155 The increased potency and durability of VRC07-523LS relative to VRC01 may help 156 address a key question regarding bnAbs as a potential HIV prevention tool, namely the 157 feasibility of their administration. More potent and longer-acting bnAbs can be 158 administered less frequently and at lower doses and thus at lower cost. The route of 159 administration is another important feasibility consideration, influenced by both dose and volume. In the AMP studies, the necessary dose and volume of the less potent 160 161 VRC01 required IV administration. While IV administration was well-tolerated in the 162 AMP studies, the World Health Organization (WHO)'s 2022 target product profile for 163 HIV prevention bnAbs reflects a preference for subcutaneous (SC) or intramuscular (IM) 164 injection, particularly for broad programmatic deployment in low and middle income countries (LMICs) (11). 165 166 In planning for an eventual efficacy trial with combination bnAb administration, we

167 conducted a phase 1 study to comprehensively assess the safety and pharmacokinetics

of VRC07-523LS at a range of doses and via several different routes of administration.

169

170

171 Methods

172 Participants and Study Design

173 HVTN 127/HPTN 087 is a multicenter, randomized, partially blinded phase 1 clinical trial to evaluate the safety and serum concentrations of VRC07-523LS, administered in 174 175 multiple doses and routes to healthy adults without HIV (**Table 1**). Participants received 176 five administrations of the assigned dose and route every four months at Weeks 0, 16, 32, 48, and 64 and were followed on study through Week 112. The product was vialed 177 at a concentration of 100 mg/mL and volume considerations limited the SC route to a 178 179 maximum of 5 mg/kg and the IM route to 2.5 mg/kg. 180 Participants were enrolled at seven clinical research sites (CRSs): Brigham & Women's 181 Hospital (Boston, MA), the Fenway Institute (Boston, MA), the University of North Carolina (Chapel Hill, NC), the University of Alabama (Birmingham, AL), Ponce de Leon 182 CRS (Atlanta, GA), Columbia University (New York, NY), and the Centre Hospitalier 183 184 Universitaire Vaudois (Lausanne, Switzerland). Volunteers were eligible if they were between 18 and 50 years of age, without HIV-1, in good overall health, and unlikely to 185 acquire HIV during the study period based on behaviours reported within the 12 months 186 prior to enrollment (12). The study was approved by the Institutional Review Boards of 187 188 each participating CRS and all participants provided written informed consent. The HIV Vaccine Trials Network (HVTN) Safety Monitoring Board (SMB) provided safety 189 oversight. The trial was registered with ClinicalTrials.gov (NCT03387150). 190 191 Participants were randomized through an Internet-based randomization system in

192 blocks. Group 6 was added via an amendment after enrollment of Groups 1 to 5 began.

Participants and study staff were unblinded to group assignment (Groups 1 through 6)
but blinded to antibody versus placebo within Group 6.

195

196 Safety Assessments

197 Following the first study product administration (SPA), participants were monitored for at

least 60 minutes to assess for solicited local and systemic adverse events (AEs),

including pain/tenderness at the infusion or injection site, fever, malaise, myalgia,

headache, chills, arthralgia, nausea, urticaria, non-exertional dyspnea, non-exertional

tachycardia, generalized pruritus, facial flushing, and unexplained diaphoresis. If no

202 reactions occurred after the first administration, in-clinic monitoring after subsequent

203 SPAs could decrease to 30 minutes. Participants completed daily symptom diaries to

204 document solicited AEs for three days following each infusion or injection. Symptom-

targeted physical exams and laboratory assays (complete blood count with differential,

creatinine, alanine aminotransferase, urine dipstick, pregnancy testing, and HIV testing)

were performed for safety monitoring at prespecified intervals throughout the study.

208 Unsolicited AEs were collected throughout the study.

209

210 Pharmacokinetics Studies

211 Enzyme Linked Immunosorbent Assay (ELISA)

212 An ELISA assay was used to measure serum concentrations of VRC07-523LS between

the first and second SPA. These concentrations were quantified in 96 well plates on a

214 Beckman Biomek based automation platform. The monoclonal antibody (mAb) 5C9 was coated onto Immulon-4HXB microtitre plates overnight at 4°C. Plates were then washed 215 and blocked (10% FBS in PBS) for 2 hours at room temperature. Duplicate serial 3-fold 216 217 dilutions covering the range of 1:100 – 1:24 300 of the test sample were incubated 2 218 hours at 37°C followed by Horseradish Peroxidase (HRP) – labeled goat anti-human antibody (1 hour at 37°C) and TMB substrate (15 minutes at room temperature). Color 219 development was stopped by addition of sulfuric acid and plates were read within 30 220 221 minutes at 450 nm via the Molecular Devices Paradigm plate reader. Linear regression 222 of a standard curve of VRC07-523LS covering the range from 0.91 to 5 ng/mL was utilized to quantitate sample concentrations based upon the average of sample dilutions 223 within the range of the assay. The lower limit of quantification (LLoQ) of the ELISA 224 225 assay was 1 µg/mL. Serum concentration data from 121 volunteers were measured by the ELISA assay on Target Visit Days 0, 3, 6, 28, 56, 84, and 112 (second SPA). 226

227

228 Binding Antibody Multiplex Array (BAMA)

For programmatic reasons, the BAMA assay was used to measure serum 229 230 concentrations of VRC07-523LS in samples collected after the second SPA in a subset 231 of participants enrolled in each treatment group. Serum VRC07-523LS concentrations 232 were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to measure infused VRC07-523LS by its ability to bind anti-idiotype antibody captured on 233 fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 234 235 Luminex assay (13-16). The Bioplex software provides 2 readouts: a background-236 subtracted median fluorescent intensity (MFI), where background refers to a plate level

control (i.e., a blank well containing antigen-conjugated beads run on each plate), and a
 concentration based on a standard curve using a 5PL curve fit. Each sample was run in
 duplicate.

240 VRC07-523LS was titrated and combined to create a standard curve used to determine concentration of the diluted samples. The negative controls were CH58 (an irrelevant 241 242 mAb) and blank beads. Samples with VRC07-523LS concentrations below 0.01 µg/mL at a dilution of 1:100 were truncated at 0.01 µg/mL for plotting purposes. All samples 243 are shown in the plot, including concentrations below the LLoQ. Samples with 244 245 concentrations above the LLoQ at a 1:100 dilution were further tested at various dilution factors to obtain MFIs in the linear range of the standard curve, and the in-well 246 247 concentration closest to the EC_{50} of the 5PL standard curve was reported. Several criteria were used to determine if data from an assay were acceptable and 248 could be statistically analyzed. The standard curve EC₅₀ values and MFI values were 249 250 tracked against historical data in Levey Jennings and points with an MFI > 100 must 251 have had a %CV <20% between replicates. Any sample without at least 2 observed 252 concentrations in agreement with each other, or with baseline MFI > 1000 was repeated 253 to obtain an accurate measurement. The physiological LLoQ of the BAMA assay was 254 0.0457 µg/mL. Serum concentrations were measured using BAMA in 60 of 121 participants who received the study product (10 randomly selected participants for each 255 256 treatment group) in samples collected at target visit days 168, 224, 280, 336, 392, 448, 257 504, 560, 616, 672, 728, 784.

258

259 Neutralization activity

260	Neutralizing antibody activity against HIV-1 was measured as a function of reduction in
261	Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells as described
262	(17, 18). The assay performed in TZM-bl cells measured neutralization titres against
263	Env-pseudotyped viruses sensitive to the bnAb (i.e., bnAb-specific viruses) in each
264	group and a magnitude-breadth panel of Env-pseudotyped viruses. The assay tested
265	neutralization of a panel of Tier 2 viruses that exhibit a range of known sensitivities to
266	VRC07-523LS (Supplemental Table 1), which are H703_0646_051sN,
267	H703_1471_190s, H703_1750_140Es, H704_0726_080sN, H704_1535_030sN,
268	H704_2544_140eN01, PVO.4 (19), and a negative control Env-pseudotyped virus
269	(SVA-MLV). Serum neutralization titre was defined as the serum dilution that reduced
270	relative luminescence units (RLU) by 50% and 80% (ID $_{50}$ and ID $_{80}$) relative to the RLU
271	in virus control wells (cells + virus only) after subtraction of background RLU (cells only).

272

273 Anti-Drug Antibodies

Anti-drug antibodies (ADA) were assayed and characterized using a tiered bridging assay testing strategy, in which ADAs act to bridge labeled drug product and are detected in an electrochemiluminescent assay, as previously described (20). In Tier I, a sensitive binding assay determined if samples may have ADA present. In Tier II, the response was confirmed by establishing the specificity of the response by competition with free drug. In Tier III, the ADA response magnitude was characterized by titration.

280

281 Statistical Methods

282 Endpoints

- 283 The first primary endpoint was the safety and tolerability of different doses of VRC07-
- 523LS administered IV, SC, and IM by repeat dosing every 16 weeks for a total of 5
- administrations. The second primary endpoint was the serum concentrations of VRC07-
- 523LS administered IV, SC, and IM over 6 different dose/route regimens. The safety
- data analyses included data from all enrolled participants; the concentration data
- analyses included data from 121 participants who received VRC07-523LS (data from
- the three placebo recipients were excluded).

290

291 Statistical approaches

- Magnitude-breadth (MB) curves (21) were constructed by study week for ID₅₀ and ID₈₀
- separately. All statistical analyses were carried out using R version 4.0.

294

295 Population Pharmacokinetics Analysis

The population pharmacokinetic (PK) profile of VRC07-523LS in serum was described using compartmental models. The analysis considered and compared PK models with one, two, and three compartments. These candidate models were fitted to observed serum concentrations using a nonlinear mixed effects approach, including random effects to account for inter-participant variability in PK parameters. The conditional variance of the error term, given the random effects, was assumed to include two 302 additive terms: one term was proportional to the conditional expectation of the concentration; the second term was a constant. Participant-specific (individual) PK 303 parameters were assumed to follow log-normal distributions. The variance-covariance 304 305 matrix of the random effects was fully unstructured. Additionally, PK parameters were adjusted for the assay (ELISA or BAMA) used to measure concentrations. The model 306 307 was fitted using the method of maximum likelihood, implemented using the Stochastic Approximation Expectation Maximization (SAEM) algorithm. The significance of the 308 difference in each PK parameter between the two assays was evaluated using Wald 309 310 tests. Comparison of models with one, two, and three compartments was carried out using a corrected Bayes Information Criterion (BICc). Participant-specific PK 311 parameters were predicted using their empirical Bayes estimates, defined as the most 312 313 probable value of the participant-specific PK parameters, given the estimated population parameters and the data from the corresponding participant. These participant-specific 314 PK parameters were used to predict the most probable trajectory of the serum 315 316 concentration for each participant. Modeling assumptions were evaluated using weighted conditional residuals plotted as a function of study day. Model-based predicted 317 318 participant-specific (most probable) serum concentration trajectories were plotted as a 319 function of study day and compared to the observed serum concentrations. All compartmental PK analyses were conducted using MonolixSuite Version 2019R2 (22). 320 321 The area under the curve (AUC) of the VRC07-523LS serum concentration of each individual study participant after one study product administration was computed by 322 323 summing the estimate of the AUC between Days 0 and 112 computed using the 324 trapezoidal method applied to untransformed serum concentrations and the estimate of

- the AUC after Day 112 computed as exp(a+112*b)/exp(b) where a and b are the
- intercept and slope of a linear regression model describing log-serum concentration as
- 327 a function of time since baseline and fitted to serum concentrations measured in the log-
- linear portion of the pharmacokinetics of VRC07-523LS.
- 329

330 Neutralization Activity

- 331 Key secondary objectives included determining whether serum neutralizing activity is
- maintained at consistent levels after each product administration and to determine
- 333 whether serum neutralizing activity agreed with measured serum concentrations. A
- response to a given pseudovirus was considered positive if the corresponding ID₅₀ or
- ID_{80} value was > 10 or 20, depending on the starting dilution of the sample. The assay
- measured neutralisation titres against seven Env-pseudotyped viruses to determine
- bnAbs activities against specific viruses (**Supplemental Table 1**).

338

340 **Results**

341 **Participant Characteristics and Demographics**

342 Participants were recruited between 02 February 2018 and 09 October 2018. A total of 124 participants enrolled between 28 February 2018 and 09 October 2018 at six sites in 343 the US and one in Switzerland (Figure 1). 75 participants (60%) were assigned female 344 345 sex at birth; seven participants reported that they were gender non-conforming. 71 participants (57%) identified as White, 28 (23%) as Black/African American, and 12 346 (10%) as Hispanic (**Table 2**). The median age of participants at enrollment was 28 347 years. Ninety-five participants (77%) received all five injections or infusions. The final 348 SPA occurred on 10 January 2020, prior to the arrival of COVID-19 in the US or 349 Switzerland, however pandemic restrictions had a considerable impact on follow-up 350 visits. To ensure that sites could collect safety information, remote visits were permitted 351 to be conducted, but no samples could be collected until local safety restrictions allowed 352 in-person visits. The final study visit occurred on 04 December 2020. Sample availability 353 is shown in Figure 1. 354

355

356 Safety and Tolerability

VRC07-523LS was safe and generally well-tolerated at all doses and via all routes
 administered (Figure 2). Mild to moderate injection site pain and/or tenderness was
 noted by most participants randomized to receive VRC07-523LS by the SC or IM
 routes. Erythema and/or induration at the injection site was noted by most participants

in the SC groups but was generally mild to moderate. Malaise/fatigue and headaches
 were the most common systemic solicited AEs.

363 The majority (98 [79%]) of participants experienced at least one AE during the study, 364 but the vast majority were deemed unrelated to VRC07-523LS administration. Of the sixteen unsolicited AEs deemed related to VRC07-523LS, four began as solicited AEs 365 366 that continued past the diary period and nine (7% of participants) were isolated 367 symptoms or combinations of symptoms suggestive of infusion-related reactions, similar 368 to those seen with VRC01 administration (23). These symptoms included generalized 369 pruritis, facial flushing, chills, myalgia, arthralgia, nausea, headache, and diaphoresis. In three participants in the 20 mg/kg IV group, these combinations of symptoms were 370 371 deemed to be consistent with infusion reactions. No pregnancies or HIV acquisitions 372 were reported during the study. There were three serious adverse events (SAEs) all deemed unrelated to VRC07-523LS: Staphylococcal infection, pyrexia in a returned 373 374 traveller, and urinary calculus.

375 Participants completed acceptability surveys at every SPA visit to assess their opinions 376 on elements of the administration including discomfort, overall time commitment, and 377 willingness to receive products via their specific route (**Supplemental Table 2**). In general, participants reported that the discomfort, pain, and anxiety related to the SPA 378 379 was acceptable, although participants in the two SC groups were more likely to say that these were unacceptable (Supplemental Tables 2A-2C). The time required for SPA 380 was considered acceptable by most participants (>87% across all visits and groups; 381 382 **Supplemental Table 2D**). Most participants were very or somewhat willing to use the same method to prevent a serious illness (Supplemental Table 2E) and most would 383

384	recommend that method to a friend at risk of HIV, but this recommendation was lowest
385	for participants in the SC groups at the final SPA (77.4% yes; Supplemental Table 2F).
386	Four participants reported adverse social impacts (12) as a result of their participation,
387	mostly in the realm of their interpersonal relationships.
388	

389 Anti-drug Antibody

The presence and magnitude of ADA in serum were measured using a tiered "bridging

assay" to detect ADA from serum samples obtained at Months 0, 2, 4, 8, and 16. A total

of 124 participant samples were tested from Month 0, 1 from Month 2, 2 from Month 4,

114 from Month 8 and 96 from Month 16. A single participant enrolled in Group 4 (SC

route, 2.5 mg/kg VRC07-523LS) exhibited a confirmed ADA response at Month 8 (4

months after the 2^{nd} SPA) with a low titre of 1:9 but was ADA negative at Month 16 (4

396 months after the 4^{th} SPA).

397

398 Serum Concentrations

At a given dose, peak and trough concentrations were highest in the IV groups and
lowest in the SC groups. Peak geometric mean titres (GMT) after the first dose, as
measured by ELISA, were noted on Day 3, with GMT (95% CI) of 28.98 µg/mL (25.16,
33.39) in the 2.5 mg/kg IV group, 58.51 µg/mL (49.41, 69.29) in the 5 mg/kg IV group,
257.22 µg/mL (127.52, 518.86) in the 20 mg/kg IV group, 10.84 µg/mL (8.84, 13.3) in
the 2.5 mg/kg SC group, 22.78 µg/mL (20.05, 25.88) in the 5 mg/kg SC group, and

405	16.35 $\mu g/mL$ (14.71, 18.18) in the 2.5 mg/kg IM group (Figure 3; Supplemental Figure
406	1). The lowest pre-administration troughs were noted on Day 112, just before the
407	second infusion, with GMT (95% CI) of 3.4 $\mu\text{g/mL}$ (2.51, 4.61) in the 2.5 mg/kg IV group,
408	6.5 $\mu g/mL$ (5.6, 7.54) in the 5 mg/kg IV group, 27.2 $\mu g/mL$ (23.85, 31.01) in the 20
409	mg/kg IV group, 0.97 μ g/mL (0.65, 1.44) in the 2.5 mg/kg SC group, 3.09 μ g/mL (2.2,
410	4.33) in the 5 mg/kg SC group, and 2.61 $\mu\text{g/mL}$ (2.05, 3.31) in the 2.5 mg/kg IM group
411	(Figure 3; Supplemental Figure 1).
412	We compared the area under the curve (AUC) of the VRC07-523LS levels for the
413	various doses and routes following the first administration. As a measure of exposure to
414	VRC07-523LS, the AUC was higher in the 20 mg/kg IV group (Supplemental Figure
415	2A). When corrected for the administered dose, the three IV groups had higher AUCs
416	than either the SC or the IM groups (Supplemental Figure 2B), reflecting the lower
417	bioavailability of the SC and IM routes.
418	The subsequent four-month post-administration troughs were slightly higher than after
419	the first dose and quite similar between the second and fifth study product
420	administrations (Figure 4; Supplemental Figure 3). This result suggests that there was
421	very little in vivo accumulation of VRC07-523LS with the 16-weekly administration
422	schedule, at least up to five consecutive doses. Furthermore, the relatively consistent
423	levels of VRC07-523LS measured between the second and fifth administrations given at
424	a frequency of four months suggests that a near steady state is established after the
425	second administration with peaks and troughs determined by the dose and route.
426	

427 **Population PK Analysis**

428 We conducted a population PK analysis of VRC07-523LS serum concentrations 429 measured in healthy participants after up to five SPA via the IV, SC, or IM routes at 430 various doses. Data were collected at 19 timepoints between Day 0 and Day 784, covering the period from baseline up to after the fifth SPA. The BICc determined that 431 432 the two-compartment PK model was better at describing serum concentrations of 433 VRC07-523LS than PK models with one or three compartments. The two-compartment 434 PK model predicted well serum concentrations across routes of administration and 435 doses (Figure 5; Supplemental Figures 4A-F). Estimated PK parameters are summarized in Supplemental Table 3. 436 Based on data measured between the first and second SPA using ELISA, the 437 elimination half-life of VRC07-523LS was estimated as 42.43 days (SE = 0.75). Its 438 bioavailability was estimated as 0.40 (SE = 0.0013) after SC administration, and 0.57 439

440 (SE = 0.03) after IM administration, as compared with IV administration. The difference

between the bioavailability after SC and IM administrations was significant (p<0.001).

The average clearance of VRC07-523LS was 0.11 L/d (SE = 0.0031).

The analyses of serum concentrations measured after the first SPA using ELISA versus

after the second SPA using BAMA found significantly different PK parameters, namely

estimated clearance (0.15 L/d versus 0.11 L/d; p < 0.001), central compartmental

volume (3.18 versus 2.72, p < 0.001), peripheral compartmental volume (3.74 versus

447 3.59, p< 0.001), and inter-compartmental clearance (1.18 L/day versus 0.49 L/day; p <

448 0.001). The distribution and elimination half-lives were also significantly different (4.61

days versus 1.17 days, p < 0.001; and 42.67 days versus 42.43 days, p < 0.001)

450 following the first SPA (by ELISA) and following the second SPA (by BAMA). 451 respectively (**Supplemental Figure 5**). Although these differences are statistically significant, the absolute difference is guite small and unlikely to be clinically significant. 452 453 Differences between the bioavailability and absorption rate constant based on BAMA 454 versus ELISA derived data could not be estimated due to numerical instability occurring when fitting a population PK model that allowed for differences in these parameters 455 between the two assays. This instability may be due to the differences in sampling 456 457 frequency between the first and second SPA versus the less frequent sampling 458 following the second SPA. 459 The analysis suggested that serum concentrations of VRC07-523LS increased linearly with the dose following IV and SC administrations, as evidenced by the population PK 460 461 model properly fitting data across dose levels and routes of administration (Figure 5; **Supplemental Figures 4A-F**) and the similarity of the peak and trough levels as well as 462 dose-normalized AUC across dose groups within a given route of administration 463 464 (Supplemental Figures 1 and 2).

465

466 **Neutralization Activity**

Neutralization activity was assayed at 3 time points (Weeks 8, 72, and 88 following the
first infusion of study product) in a subset of approximately 10 participants in each active
treatment group and 3 placebo recipients, as follows: 9 participants in Group 1, 10 in
Group 2, 10 in Group 3, 10 in Group 4, 10 in Group 5, 11 in Group 6, and 3 in the
Placebo group.

472	In the IV and SC groups, response magnitudes increased overall with dose at a given
473	timepoint (Figure 6; Supplemental Figure 6). Overall, response rates and magnitudes
474	at Week 72 (8 weeks after the fifth study product administration) were either
475	comparable to or slightly higher than those measured at Week 8 (8 weeks after the first
476	study product administration), again suggesting limited accumulation of VRC07-523LS
477	between the first and fifth administrations. As expected, the lowest response rates and
478	magnitudes were observed at Week 88 (24 weeks after the fifth study product
479	administration).
480	In addition to confirming that neutralization activity of VRC07-523LS is preserved
481	following in vivo administration, these results allow us to compare the established in
482	vitro ID_{80} titre with the in vivo concentration to generate a predicted protective efficacy
483	titre (PT_{80}) (35). If an in vivo neutralization threshold of 200 is required for achieving
484	potent prevention efficacy for VRC07-523LS (35), this level would only have been

486 (Figure 6).

487 At a given dose, higher serum neutralization titres were observed after IV

administrations compared to either SC or IM administrations and this was particularly

489 pronounced in the Magnitude-Breadth Area Under the Curve (MB-AUC) analysis

(Figure 7; Supplemental Figure 7). The MB-AUC plots also indicate that neutralization
activity was higher after receiving 5.0 mg/kg of VRC07-523LS via the SC route versus a
lower dose of 2.5 mg/kg of VRC07-523LS via the IV route, suggesting that the levels of
neutralization achieved by IV infusions may be reached by administering higher doses
via the SC route. For the 2.5 mg/kg dose, which was the only one given via all three

- routes, the neutralization titres were highest for the IV route, followed by the IM route,
- and lowest via the SC route. As with the neutralization titres, response rates tended to
- 497 be higher in the IV groups than in the SC or IM groups when comparing responses
- among groups that received the same dose.
- 499

501 Discussion

502 This phase 1 clinical trial highlights several key findings which have implications for the 503 design of future bnAb efficacy studies. First, a human neutralizing antibody engineered 504 for breadth, potency, and a prolonged in vivo half-life was safe and generally welltolerated when administered across a wide dose range and via different routes of 505 506 administration. Second, although the half-life of this engineered bnAb is considerably longer than that of the VRC01 antibody used in the AMP studies (24), the half-life of 507 VRC07-523LS is substantially less than VRC01LS (25). Third, while SC and IM 508 509 administration of VRC07-523LS was safe and well-tolerated and these routes have 510 notable operational advantages (11), decreased bioavailability may have implications 511 for achieving target concentrations, and inter-individual variability in PK parameters 512 observed must be considered in designing a combination bnAb efficacy study with VRC07-523LS. 513

514 In this study, we found that the serum concentrations of VRC07-523LS increased 515 linearly across the dose range administered in this study. We also found that the peak 516 and trough concentrations were highest in the IV groups and lowest in the SC groups at 517 any given dose. There was also no significant difference in the half-life of VRC07-523LS when administered by different routes. These trends were also true for VRC01 and 518 VRC01LS in other studies (25, 26), as well as for other bnAbs (27), which likely reflects 519 generalizable PK behavior of antiviral antibodies in unexposed hosts. Some studies 520 noted shorter half-lives of anti-HIV-1 bnAbs in persons living with HIV (28-30), which 521 522 has implications for use of these biologics in HIV treatment and cure studies.

523 We also found an excellent correlation between the predicted level of VRC07-523LS and the measured serum concentrations, suggesting that a two-compartment model can 524 predict the PK of this monoclonal antibody following repeated IV, SC, or IM 525 526 administrations. This correlation was robust to dose, delivery route, and method of 527 antibody measurement (ELISA vs BAMA). The high performance of these prediction models may allow future phase 1 studies to be smaller and more efficient, in terms of 528 the number of participants needed, the number of injections or infusions administered, 529 and the total length of follow-up needed to develop a robust PK model. This finding in 530 531 turn has the potential to facilitate moving bnAbs into efficacy studies. 532 Data from this study has informed ongoing studies of combination bnAbs as it is likely 533 that combinations of bnAbs targeting complementary epitopes on Env will be necessary to provide sufficient protection in vivo (6). VRC07-523LS has been evaluated in 534 combination with the non-LS-mutated bnAbs PGT121, PGDM1400, and 10-1074, in the 535 HVTN 130/HPTN 089 study (31). PGT121 and 10-1074 target the V3 glycan epitope 536 whereas PGDM1400 targets the V1V2 region, and all three, while narrower in breadth 537 538 than VRC07-523LS, are considerably more potent (32). As bnAbs with longer half-lives 539 are likely to be more feasible for deployment (5, 6), VRC07-523LS is also being evaluated in combination with an engineered version of PGT121 called PGT121.414.LS 540 in the recently completed HVTN 136/HPTN 092 trial [NCT04212091]. In the HVTN 541 542 140/HPTN 101 study [NCT05184452], VRC07-523LS and PGT121.414.LS were tested in combination with PGDM1400LS. In the multi-phase CAPRISA 012 studies (33, 34), 543 VRC07-523LS was tested with CAP256V2LS, a V1V2 targeting bnAb which is 544 particularly potent against clade C isolates of HIV-1. Some of these studies include 545

546 modified SC administration methods (for example, SC infusion via pump in HVTN 136/HPTN 092 [NCT04212091] and co-administration of bnAbs with hyaluronidase in 547 CAPRISA 012 (33, 34)) to try to increase the bioavailability of the SC route. 548 549 Furthermore, analysis of mucosal tissue and secretion PK of VRC07-523LS at rectal 550 and vaginal sites is ongoing in the HVTN 128 trial [NCT03735849], which is particularly 551 relevant as the vast majority of HIV-1 infections occur at mucosal sites. 552 Recently, the correlates of risk analyses from the AMP studies were used to generate a model of protective efficacy (PT₈₀) that can be used for predicting efficacy of bnAbs 553 554 against HIV-1 (35). The PT₈₀ model combines in vitro IC₈₀ neutralization data with in 555 vivo PK data to provide an estimate of protection against a population of viruses to 556 which participants may be exposed (35). This model was used to predict prevention 557 efficacy (PE) of a hypothetical repeat of the AMP studies using the broader and more 558 potent mAb VRC07-523LS as a single agent and suggested that PE in this case could 559 have been approximately 79% against clade C viruses (35). However, the PT₈₀ model 560 also suggested that a high-dose three bnAb combination regimen including VRC07-561 523LS could have a PE of approximately 95% against a panel of recent clade C isolates 562 (35). Ultimately, large efficacy studies will need to be performed with combination bnAbs to assess their ability to prevent HIV-1 acquisition. 563 UNAIDS recently released their preferred product characteristics (PPC) for mAbs for 564

HIV-1 prevention, noting that longer-acting mAbs could play an important role in future pre-exposure prophylaxis (PrEP) campaigns as many people may opt for an injectable product rather than anti-retroviral pills or intra-vaginal rings (11). Long-acting prevention methods may be desirable for key populations such as pregnant women and adolescent

- ⁵⁶⁹ girls who are at high risk of HIV-1 acquisition, particularly in sub-Saharan Africa (11).
- 570 While the UNAIDS PPC expressed a preference for SC administration, as noted for
- 571 other low-volume mAbs for non-infectious indications (36), the participants in our SC
- 572 groups had a somewhat less enthusiastic opinion about acceptability of SC
- administration compared to the other groups. Furthermore, the lower bioavailability
- observed for VRC07-523LS combined with the high concentrations likely needed to
- 575 exceed the PT₈₀ for circulating strains of HIV-1 argue that IV administration is more
- 576 likely to be successful for HIV-1 prevention until the technical hurdles which impact
- 577 injection volume and potency are overcome.

579 Acknowledgments

We wish to thank our volunteers for their generous participation in this study as well as
the dedicated staff at the HVTN and HPTN clinical research sites and affiliated
laboratories who made the study possible. We also wish to thank Mindy Miner and
Nicole Na for editorial assistance as well as Jessica Fogel and Fatima Laher for their
thoughtful comments on the manuscript.

585

586 The HVTN 127/HPTN 087 Study Group: In addition to the authors of this article,

587 members of the HVTN 127/HPTN 087 Study Group consist of: Myron Cohen, Lawrence

588 Corey, Jill Zeller, Gina Escamilla, Gail Broder, April Randhawa, Jessica Andriesen,

589 Amanda Brown, Carter Bentley, Jontraye Davis, Huiyin Lu, Jignesh Patel, Tahereh

590 Nourbakhsh, Shannon Grant, Rotrease Reagan, Jamel Young, Noshima Darden-Tabb,

Jorge Benitez, Brett Gray, Joshua A. Weiner, Gabriela Kovacikova, Chanc E,

592 VanWinkle Orzell, Maureen Furlong, Nathan Erdmann, Sonya Heath, Michel Obeid,

593 Rosemary Hottinger, Rossi Fish, Adrianna Boulin, Gary Daffin, Marcy Gelman, Colleen

594 Kelley, Jane A. Kleinjan, Jon A. Gothing, Elvin J. Fontana-Martinez, Michael S.

595 Seaman, Raphael Dolin, and Jennifer A. Johnson.

597 Figure Legends

- 598 **Figure 1.** CONSORT diagram illustrating participant flow through the study.
- 599 **Figure 2.** Solicited adverse events (AEs) reported by participants after product
- administration. Local (A) and systemic (B) solicited AEs were collected for three days
- following each administration of VRC07-523LS or placebo. P6 = placebo IM; T1 = 2.5
- mg/kg IV; T2 = 5 mg/kg IV; T3 = 20 mg/kg IV; T4 = 2.5 mg/kg SC; T5 = 5 mg/kg SC; T6
- = 2.5 mg/kg IM.
- **Figure 3.** VRC07–523LS serum concentration (μg/mL) following first study product
- administration (SPA). Geometric means and 95% confidence intervals are presented,
- 606 by treatment group and target day.

Figure 4. VRC07-523LS concentrations measured after product administration every

four months at specified doses and routes. Peak levels were only assessed after the

- 609 first dose. Levels following the second and subsequent doses were assessed by binding
- 610 antigen multiplex assay (BAMA).
- **Figure 5.** Measured serum concentrations of VRC07-523LS vs concentrations

612 predicted by a two-compartment pharmacokinetic model.

- **Figure 6.** Neutralization activity of participant serum following VRC07-523LS
- administration against seven HIV-1 isolates collected from incident HIV-1 acquisition
- events of placebo recipients in the AMP trials. ID₈₀ titre is shown.
- **Figure 7.** Magnitude-breadth curves for participant serum following VRC07-523LS
- administration against a panel of HIV-1 isolates collected from incident HIV-1 acquisition

- of placebo recipients in the AMP trials. ID₈₀ titre is shown at Week 8 (A) and Week 72
- 619 **(B)**.
- 620
- 621

622 **References**

623

624 Cohen MS, Gamble T, McCauley M. Prevention of HIV Transmission and the HPTN 052 Study. 1. 625 Annu Rev Med. 2020;71:347-60. 626 Delany-Moretiwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for 2. 627 the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 628 2022;399(10337):1779-89. 629 3. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV 630 Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608. 631 UNAIDS. Global HIV & AIDS statistics — Fact sheet [Available from: 4. 632 https://www.unaids.org/en/resources/fact-sheet. 633 5. Karuna ST, Corey L. Broadly Neutralizing Antibodies for HIV Prevention. Annu Rev Med. 634 2020;71:329-46. 635 Walsh SR, Seaman MS. Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol. 6. 636 2021;12:712122. 637 Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a 7. 638 broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J 639 Virol. 2014;88(21):12669-82. 640 8. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor 641 function improves protection against primate SHIV infection. Nature. 2014;514(7524):642-5. 642 Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody 9. 643 half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157-9. 644 Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, et al. Safety and 10. 645 pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a 646 phase 1 dose-escalation clinical trial. Lancet HIV. 2019;6(10):e667-e79. 647 WHO. WHO preferred product characteristics for monoclonal antibodies for HIV prevention 11. 648 [Available from: https://www.who.int/publications/i/item/9789240045729. 649 Andrasik MP, Sesay FA, Isaacs A, Oseso L, Allen M. Social Impacts Among Participants in HIV 12. 650 Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials. J Acquir Immune Defic Syndr. 651 2020;84(5):488-96. 652 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-13. 653 correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86. 654 Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, et al. Vaccine-induced plasma IgA 14. 655 specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl 656 Acad Sci U S A. 2013;110(22):9019-24. 657 Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to 15. 658 transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG 659 antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 660 2008;82(24):12449-63. 661 Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env 16. 662 V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl 663 Med. 2014;6(228):228ra39. 664 Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol 17. 665 Biol. 2009;485:395-405.

Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and
validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J
Immunol Methods. 2014;409:131-46.

669 19. Mkhize NN, Mapengo RE, Bekker V, Modise T, Kgagudi P, Lambson BE, et al., editors.

670 Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP 671 trial (HVTN 703/HPTN 081). HIVR4P; 2023; Virtual.

672 20. Bharadwaj P, Riekofski C, Lin S, Seaman MS, Garber DA, Montefiori D, et al. Implementation of a 673 three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific

broadly neutralizing antibodies. J Immunol Methods. 2020;479:112764.

- Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous Evaluation of the Magnitude and
 Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine
 Development. Stat Biopharm Res. 2009;1(1):81-91.
- Traynard P, Ayral G, Twarogowska M, Chauvin J. Efficient Pharmacokinetic Modeling Workflow
 With the MonolixSuite: A Case Study of Remiferitanil. CPT Pharmacometrics Syst Pharmacol.
 2020;9(4):198-210.

Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, et al. Infusion Reactions
 After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results

- From the Phase 2b Antibody-Mediated Prevention Randomized Trials. J Acquir Immune Defic Syndr.2022;89(4):405-13.
- Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, et al. Pharmacokinetics and
 predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated
 Prevention (AMP) trials. EBioMedicine. 2021;64:103203.
- 688 25. Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and 689 pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label 690 clinical trial in healthy adults. PLoS Med. 2018;15(1):e1002493.
- Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, et al. Safety, pharmacokinetics,
 and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal
 antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS
 Med. 2017;14(11):e1002435.
- 695 27. Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, et al. Safety, 696 pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 697 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS One.
- 698 2019;14(8):e0219142.
- Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, et al. Safety, pharmacokinetics and
 antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized,
 placebo-controlled, phase 1 clinical trial. Nat Med. 2021;27(10):1718-24.
- Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of
 triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical
 trial. Nat Med. 2022;28(6):1288-96.
- 70530.Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of706combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24(11):1701-7.70724
- 70731.Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, et al. Safety,
- tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations
- of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered
- intravenously to HIV-uninfected adults: a phase 1 randomised trial. Lancet HIV. 2023;10(10):e653-e62.
- Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations
 of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS
- 713 Pathog. 2016;12(3):e1005520.

714 33. Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, et al. Assessing the safety 715 and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with

VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B

phase I clinical trial. BMJ Open. 2020;10(11):e042247.

718 34. Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, et al. Safety and

pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered

with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-

rescalation, randomised controlled trial. Lancet HIV. 2023;10(4):e230-e43.

722 35. Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, et al. Neutralization titer

biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022;28(9):1924-32.

72436.Melichar B, Studentova H, Kalabova H, Vitaskova D. Role of subcutaneous formulation of

trastuzumab in the treatment of patients with HER2-positive breast cancer. Immunotherapy.

726 2014;6(7):811-9.

727

Table 1. Study schema

<u> </u>								
Group	N	Dose	Route	Month	Month	Month	Month	Month
Group	IN	D03e	Noule	0	4	8	12	16
T1	19	2.5 mg/kg	IV	Х	Х	Х	Х	Х
T2	19	5 mg/kg	IV	Х	Х	Х	Х	Х
T3	21	20 mg/kg	IV	Х	Х	Х	Х	Х
T4	21	2.5 mg/kg	SC	Х	Х	Х	Х	Х
T5	20	5 mg/kg	SC	Х	Х	Х	Х	Х
T6	21	2.5 mg/kg	IM	Х	Х	Х	Х	Х
P6	3	Placebo	IM	Х	Х	Х	Х	Х

733 IV – intravenous; SC – subcutaneous; IM – intramuscular

736 Table 2. Participant demographics

	Female	Male	Total
Black or African-American	19	9	28 (23%)
Asian	3	3	6 (5%)
White	41	30	71 (57%)
Other	6	2	8 (7%)
Multi-racial	6	5	11 (9%)
Hispanic	7	5	12 (10%)
Non-Hispanic	68	44	112 (90%)
Total	75 (60%)	49 (40%)	124

Figure 1.

HVTN 127/HPTN 087




Figure 1. CONSORT diagram.




Figure 2. Solicited adverse events (AEs). Local (A) and systemic solicited AEs were collected for three days following each administration. P6 = placebo IM; T1 = 2.5 mg/kg IV; T2 = 5 mg/kg IV; T3 = 20 mg/kg IV; T4 = 2.5 mg/kg SC; T5 = 5 mg/kg SC; T6 = 2.5 mg/kg IM.

HVTN 127/HPTN 087

Figure 3.




Figure 3: VRC07–523LS serum concentration (μ g/mL) following first study product administration (SPA). Geometric means and 95% confidencce intervals are presented, by treatment group and target day.

Figure 4

HVTN 127/HPTN 087




Figure 4. VRC07-523LS concentrations measured after product administration every four months at specified doses and routes. Peak levels were only assessed after the first dose. Levels following the second and subsequent doses were assessed by binding antigen multiplex assay (BAMA).

HVTN 127/HPTN 087






Figure 5. Measured serum concentrations of VRC07-523LS vs concentrations predicted by a two-compartment pharmacokinetic model.

Figure 6

HVTN 127/HPTN 087





Figure 6. Neutralization activity of participant serum 8 weeks following their first VRC07-523LS administration against seven HIV-1 isolates collected from incident HIV-1 acquisition events in placebo recipients in the AMP trials. ID_{s0} titre is shown.

HVTN 127/HPTN 087



T1: IV 2.5 mg/kg, n=9, AUC=1.229
 T2: IV 5 mg/kg, n=10, AUC=1.431
 T3: IV 20 mg/kg, n=10, AUC=1.988
 T4: SC 2.5 mg/kg, n=10, AUC=0.995
 T5: SC 5 mg/kg, n=10, AUC=1.160
 T6: IM 2.5 mg/kg, n=11, AUC=1.089

Figure 7. Magnitude-breadth curves for participant serum following VRC07-523LS administration against a panel of HIV-1 isolates collected from incident HIV-1 acquisition events in placebo recipients in the AMP trials. ID_{s0} titre is shown at Week 8 (**A**) and Week 72 (**B**).

Figure 7